Novapio Plus (Metformin Hydrochloride, Pioglitazone)

Metformin Hydrochloride, the active ingredient in Novapio Plus, is a biguanide presented as an oral tablet for oral use. It is combined with pioglitazone, a thiazolidinedione, to treat type 2 diabetes mellitus in adult patients when monotherapy is insufficient and helps improve glycemic control through complementary mechanisms.

GNH USA supplies Novapio Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across Europe, Asia and the Americas.

Novapio Plus, a combination antidiabetic therapy, is indicated for management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control when diet, exercise, and monotherapy are inadequate. - Adjunct to metformin therapy: provides additional glucose‑lowering effect when metformin alone does not achieve target levels. - Adjunct to pioglitazone therapy: enhances insulin sensitivity when pioglitazone alone is insufficient.

Novapio Plus may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Weight gain: modest increase associated with fluid retention. - Peripheral edema: swelling of the lower extremities.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Congestive heart failure: exacerbation due to fluid retention. - Bladder cancer risk: potential increased incidence with long‑term pioglitazone use.

When prescribing Novapio Plus, clinicians should consider several safety aspects.

- Renal function: assess before initiating and monitor periodically. - Hepatic function: evaluate because both agents are metabolized hepatically. - Cardiovascular status: monitor for signs of heart failure, especially with pioglitazone. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Lactic acidosis risk: discontinue if the patient develops severe infection, dehydration, or hypoxia. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Novapio Plus can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Cimetidine: may increase metformin plasma concentrations. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise pioglitazone levels. - Alcohol: heightens risk of lactic acidosis. - Insulin secretagogues (e.g., sulfonylureas): may precipitate hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: can exacerbate fluid retention and edema. - ACE inhibitors or ARBs: monitor renal function and potassium. - Beta‑blockers: may mask hypoglycemia symptoms.